Thinking of joining a study?

Register your interest

NCT04629547 | RECRUITING | Sleep

Sleep Trial to Prevent Alzheimer's Disease

Washington University School of Medicine

Information provided by (Responsible Party):

Brendan Lucey

Brief Summary:

The purpose of this study is to determine if treatment with the sleep aid suvorexant can decrease the rate of amyloid-β (Aβ) accumulation in the brain.

Condition or disease


Alzheimer Disease


Suvorexant 20 mg




Detailed Description:

This study will investigate if long-term treatment with suvorexant will slow amyloid-β accumulation in the brain. Amyloid-β is a protein involved in the disease process leading to Alzheimer's disease. This study will evaluate if suvorexant can decrease the amount of amyloid-beta detected by plasma pT217/T217.

Estimated Enrollment : 200 participants
Primary Purpose : PREVENTION
Official Title : Sleep Trial to Prevent Alzheimer's Disease
Actual Study Start Date : 2022-05-25
Estimated Primary Completion Date : 2026-05
Estimated Study Completion Date : 2026-05

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 65 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers: 1
Inclusion Criteria
  • * Male or female.
  • * Any race or ethnicity.
  • * Participants must be age ≥65 years and able to sign informed consent.
  • * Global Clinical Dementia Rating (CDR) 0.
  • * Willing and able to undergo study procedures.
Exclusion Criteria
  • * History of reported symptoms suggestive of restless legs syndrome, narcolepsy or other central disorder of hypersomnolence, or parasomnia
  • * Actigraphic sleep efficiency ≥85%.
  • * Abnormal movement of the non-dominant arm (would affect actigraphy data in unpredictable ways).
  • * STOP-Bang score ≥ 5 for participants without PAP
  • * Untreated OSA with AHI ≥15 on home sleep test
  • * Treated sleep apnea with PAP non-compliance
  • * PAP compliance is defined as \>= 4 hours per night \>70% of the nights
  • * Plasma A-beta and tau test with a plasma p-tau 217% ≤0.82
  • * Stroke.
  • * Chronic kidney disease defined as patients with markers of kidney damage or eGFR of \< 45 ml/min/1.73m2.
  • * Hepatic impairment defined as AST and/or ALT \> 2x upper limit of normal (normal limits AST: 11-47 IU/L, ALT: 6-53 IU/L).
  • * HIV/AIDS.
  • * Body mass index \>35.
  • * History of substance abuse or alcohol abuse in the proceeding 6 months.
  • * Regular alcohol consumption 3 or more days a week over the last 6 months. Regular alcohol consumption is defined as having more than 2 alcoholic beverages within 3 hours of bedtime. Participants that agree to reduce alcohol consumption during the study may not be excluded.
  • * History of presence of any clinically significant medical condition, behavioral or psychiatric disorder, or surgical history based on medical record or participant report that could affect the safety of the participant or interfere with study assessments or in the judgement of the Principal-Investigator (PI) if participant is not a good candidate.
  • * Has any medical condition that, in the PI's opinion, could increase risk to the participant, limit the participant's ability to tolerate the research procedures, or interfere with the collection/analysis of the data. Potential medical conditions that will be exclusionary at the PI's discretion
    • * Cardiovascular disease requiring medication except for controlled hypertension.
    • * Pulmonary disease.
    • * Type I diabetes.
    • * Neurologic or psychiatric disorder requiring medication.
    • * Tobacco use.
    • * Use of sedating medications.
    • * Use of medications that interact with suvorexant (if cannot be discontinued)
    • * Abnormal safety labs
    • * History of current suicidal ideations.
    • * Currently pregnant or breast-feeding.
    • * In the opinion of the PI, the participant should be excluded due to an abnormal physical examination.
    • * Must not have participated in any clinical trial involving a study drug or device within the 30-days prior to study enrollment.
    • * Must not participate in another drug or device study prior to the end of this study participation.
    • Exclusion criteria for optional lumbar punctures
    • -• Contraindication to lumbar puncture (anticoagulants; bleeding disorder; allergy to lidocaine or disinfectant; prior central nervous system or lower back surgery).

Sleep Trial to Prevent Alzheimer's Disease

Location Details


Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.



United States, Missouri

Washington University School of Medicine

Saint Louis, Missouri, United States, 63110